Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Chinese Adults With Nonsegmental Vitiligo
NCT07865312Phase 3Not yet recruiting
- Sponsor
- Dermavant Sciences
- Start
- Nov 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nonsegmental vitiligo (NSV) comparing Povorcitinib phosphate with Placebo (2 arms). Primary endpoint: Proportion of participants achieving >=75% improvement from baseline in Face Vitiligo Area Scoring Index at 52 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
povorcitinib
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT07865312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07865312.